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Novelty and impact 
The mitotic kinesin KIF14 is overexpressed and is a prognostic indicator in multiple 
cancers. This study examined the effect of Kif14 overexpression on cancer in vivo for 
the first time, using a transgenic murine retinoblastoma model. Kif14 overexpression 
accelerated retinoblastoma initiation, growth rate, progression, and total tumor burden 
in these mice. These findings confirm that Kif14 can promote tumor progression in 
vivo, further validating KIF14 as an oncogene and potential therapeutic target. 
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Abstract 
The mitotic kinesin KIF14 has an essential role in the recruitment of proteins required 
for the final stages of cytokinesis. Genomic gain and/or overexpression of KIF14 has 
been documented in retinoblastoma and a number of other cancers, such as breast, 
lung and ovarian carcinomas, strongly suggesting its role as an oncogene. Despite 
evidence of oncogenic properties in vitro and in xenografts, Kif14’s role in tumor 
progression has not previously been studied in a transgenic cancer model. Using a 
novel Kif14 overexpressing, simian virus 40 large T-antigen retinoblastoma (TAg-
RB) double transgenic mouse model, we aimed to determine Kif14’s role in 
promoting retinal tumor formation. Tumor initiation and development in double 
transgenics and control TAg-RB littermates were documented in vivo over a time-
course by optical coherence tomography, with subsequent ex vivo quantification of 
tumor burden. Kif14 overexpression led to an accelerated initiation of tumor 
formation in the TAg-RB model and a significantly decreased tumor doubling time 
(1.8 vs. 2.9 weeks). Moreover, overall percentage tumor burden was also increased by 
Kif14 overexpression. These data provide the first evidence that Kif14 can promote 
tumor formation in susceptible cells in vivo. 
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Introduction 
Retinoblastoma is the most common childhood intraocular malignancy, affecting 
approximately 1 in 17,000 live births, translating to roughly 8,000 new cases a year 
globally.
1
 Retinoblastoma is the prototypic genetic cancer and has long been a major 
source of scientific discovery. It is typically initiated by the biallelic loss of the RB1 
gene, which encodes the tumor suppressor, pRB. Although the biallelic loss of RB1 is 
(usually) necessary, it is not sufficient to induce retinoblastoma, instead leading to the 
benign retinoma.
2
 Subsequent mutational events are vital to evolve retinoma to 
retinoblastoma, including somatic gain of chromosome 1q32.
2, 3
 The minimal region 
of gain at 1q32 contains KIF14, which represents a candidate oncogene in the 
development of retinoblastoma.
4
 The KIF14 locus is gained in >50% of 
retinoblastomas,
5
 and this gene is over-expressed in 90% of retinoblastomas.
4, 6
 
KIF14 is a member of the kinesin superfamily;
7
 kinesins are molecular motors 
involved in intracellular transport. KIF14 is essential for cytokinesis, interacting with 
and helping to localize protein regulator of cytokinesis 1 (PRC1) and citron kinase 
(CIT).
8
 However KIF14 also has cytokinesis independent roles, including negative 
regulation of Rap1a-Radil signaling at the cell membrane.
9
 Although the exact 
molecular functions of KIF14 are still under investigation, a large body of evidence 
implicates it as an oncogene.
10
 It is gained at the DNA level in tumors such as 
hepatocellular, renal, and ovarian carcinoma.
10
 It is overexpressed in multiple cancer 
types such as breast (including in premalignant breast tissue of BRCA1/2 mutation 
carriers),
11
 lung, ovarian, hepatocellular, and brain tumors. Moreover, in these cancers 
KIF14 levels are prognostic for outcome. KIF14 knockdown decreases tumorigenicity 
in vitro and in xenografts, while overexpression enhances growth.
10
  
Despite these exciting findings, the effects of Kif14 overexpression in a transgenic 
cancer model have not previously been assessed. The recent development of a Kif14 
overexpressing transgenic mouse, constitutively expressing Kif14 under a 
cytomegalovirus promoter,
12
 makes such studies possible. Given the importance of 
KIF14 in human retinoblastoma, we sought to assess the effects of Kif14 
overexpression on tumor formation in the widely used simian virus 40 T-antigen 
expressing mouse model of retinoblastoma (TAg-RB).
13
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Methods 
Animals 
All animal experiments were approved by the Indiana University School of 
Medicine Institutional Animal Care and Use Committee (Protocol 10521) and 
adhered to all standards set forth in the ARVO Statement for the Use of Animals in 
Ophthalmic and Visual Research. By crossing transgenic mice constitutively 
overexpressing Kif14 (BDF1-Tg(pCAGGS-Kif14)#28; Accession Number 
CDB0476T, http://www.cdb.riken.jp/arg/TG%20mutant%20mice%20list.html)
12
 into 
the TAg-RB strain (CB6-Tg(TagRb)1Plm/Mmjax)
13, 14
 we generated novel 
Kif14;TAg-RB double transgenic mice. In order to ensure near-congenicity and 
minimize animal to animal variability in phenotype, the Kif14 mice (generated in a 
BDF-1 background) were first backcrossed into the C57BL/6 background for 6 
generations. Hemizygous 6th generation Kif14 backcross offspring were bred with 
hemizygous TAg-RB mice to obtain double transgenic mice of mixed sex as well as 
single transgenic TAg-RB or Kif14 littermates. Mice were genotyped as described.
12, 
14
 The mice of the desired genotypes were maintained for up to 12 weeks under 
standard housing conditions.
14
 
Imaging 
Animal eyes were imaged longitudinally from two weeks (when eyes first opened) 
to 12 weeks of age. Image-guided optical coherence tomography (OCT) and 
brightfield funduscopy were performed using a Micron III intraocular imaging system 
(Phoenix Research Labs; Pleasanton, CA). Animals were sedated with a mix of i.p. 
ketamine (17.2 mg/kg) and dexmedetomidine (0.5 mg/kg). Post sedation, the pupils 
were dilated using 1% tropicamide, followed by application of a topical hypromellose 
ophthalmic demulcent solution (Gonak; Akorn, Lake Forest, IL), which prevented the 
drying of the cornea and the formation of cataracts. After imaging the sedation was 
reversed by i.p. atipamezole (1 mg/kg). 
Quantification of OCT Images 
In order to quantify the volumes of individual tumors via OCT, we adapted a 
previously developed ellipsoid volumetric calculation method.
15
 The widest sections 
of the tumors from perpendicular planes were used to calculate ellipsoid volume (V) 
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using the formula V = 4/3πabc where a, b, and c are the radii of the three axes of the 
ellipsoid.
15
 ImageJ 1.49 (http://imagej.nih.gov) was used to measure the radii of each 
tumour from OCT images. 
Eye Preparation and Immunohistochemistry 
After intraocular imaging, cohorts of mice were euthanized at 8 and 12 weeks of 
age. Enucleated eyes were fixed in 4% paraformaldehyde overnight and then 
transferred to 70% ethanol. The eyes were processed at the Indiana University School 
of Medicine Histology Core. Whole eyes were embedded in paraffin, then 2–3 
papillary-optic nerve 5 µm sections were collected every 300 µm through each globe. 
Mayer’s hematoxylin and eosin (H&E) staining was performed as previously 
described,
14
 while adjacent sections were left unstained for immunohistochemistry 
(IHC). These sections were deparaffinized with xylenes and an ethanol series, boiled 
in citrate buffer for 5 minutes, blocked for one hour with 1% normal goat serum in 
Tris buffered saline (TBS), then probed overnight at 4°C with a TAg antibody (sc-
147, Santa Cruz Biotechnology, Santa Cruz, CA) diluted 1:200 in TBS. Detection was 
performed using the ABC Staining Kit (Santa Cruz Biotechnology) according to the 
manufacturer’s instructions. 
Quantification of Immunohistochemistry 
Bright-field micrographs were taken with an EVOS-fl digital microscope (AMG, 
Mill Creek, WA). Adjacent images of the retina on each slide were stitched together 
using Adobe Photoshop CS4. ImageJ was used to calculate the percent tumor burden 
as described.
16
 Briefly, the image was converted to 8-bit, then the retinal area was 
traced manually by an investigator masked to genotype, with area recorded by the 
region of interest function. Subsequently, the auto threshold function was used to 
select the TAg expressing cells based on IHC staining. Then, the stained pixels within 
the retina were counted using the measure function to obtain a value for tumor area in 
pixels. Total tumor area across the 6–7 slides per globe was divided by total retinal 
area to obtain the percent tumor area. To provide further validation of this approach, 
tumor areas histopathologically evident by H&E staining were assessed in a similar 
manner. 
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qPCR 
RNA was extracted from H&E stained sections (20–24 sections/eye). After coverslip 
removal in xylene, tissue was scraped into ethanol and RNA extracted using a RecoverAll 
Total Nucleic Acid Kit (Thermo Fisher, Carlsbad, CA, USA), following the manufacturer’s 
instructions. DNA was removed with a TURBO DNA-free kit (Thermo Fisher), then 90 ng 
RNA was reverse transcribed with iScript Select (Bio-Rad, Hercules, CA, USA). qPCR was 
performed on a ViiA7 thermal cycler, using Fast Advanced Master Mix and TaqMan assays 
for Kif14 (Mm01291408_m1), normalized to Hprt (Mm01545399_m1) and Tbp 
(Mm00446973_m1) (Thermo Fisher). Control reactions lacking reverse transcriptase 
confirmed removal of genomic Kif14 transgene sequence.  
Statistical Analysis 
The independent Student’s t-test was used to test for differences in tumor number 
and percent tumor burden between the control eyes and double transgenic eyes 
harvested at each time point. The extra sum of squares F-test was used to assess if the 
fitted exponential growth curve was shared between genotypes. All analyses were 
performed with GraphPad Prism v. 6.0, and differences were considered statistically 
significant at p < 0.05. 
Results 
To determine the effect of Kif14 overexpression on tumor growth in a genetic 
cancer model, we monitored retinoblastoma progression longitudinally in Kif14;TAg-
RB double transgenic mice and their single transgenic TAg-RB littermates using 
OCT. Single TAg-expressing, tumor initiating cells are first observed in the inner 
nuclear layer (INL) of the retinas of TAg-RB mice at postnatal day 8, and go on to 
form scattered pre-tumorous cell clusters by 4 weeks of age, before apoptosis kills off 
most cells, allowing surviving cells to form frank tumors.
17
 However, compared to 
this previously documented growth pattern seen in the TAg-RB mice, the Kif14;TAg-
RB double transgenics exhibited a dramatically accelerated formation of tumor-like 
clusters of hyper-reflective cells in the INL from as early as two weeks of age. In the 
double transgenic mice, these clusters filled the INL by three to four weeks of age, 
while small clusters remained scattered in the single transgenic mice (Figure 1). At 
these early ages, no pathology was evident in the fundus photographs of any mouse. 
Moreover, no abnormalities were seen in the eyes of Kif14 single transgenic mice 
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(Figure 1j). We confirmed that Kif14 mRNA was overexpressed in TAg-RB eyes (on 
average 5-fold over normal at 12 weeks), and further increased in Kif14;TAg-RB eyes 
(20-fold over normal). 
Consistent with increased tumor initiation, Kif14 overexpression in TAg-RB also 
promoted an increased tumor number per eye and increased growth rate in the double 
transgenic mice compared to the single transgenic littermates (Figure 2). OCT and 
corresponding fundus images from weeks 8 and 12 showed tumors in the INL. The 
Kif14;TAg-RB mice had large groups of tumors visualized as pale masses in the 
fundus images and hyper-reflective intraretinal masses by OCT compared to 
relatively isolated tumors in the TAg-RB mice. Indeed, counting of individual tumors 
in these images suggested a trend towards increased number of tumors per eye in the 
double transgenics at both week 8 and week 12 (Figure 2e).  
A limitation of OCT analysis of TAg-RB eyes is that the extreme periphery of the 
retina cannot be imaged effectively without distortion, therefore total tumor volume 
calculations per eye cannot be reliably performed in vivo and some tumors may not 
have been countable by this method. However, in order to monitor tumor growth rate 
over a time course, volumetric analysis using an ellipsoid volumetric estimation
15
 of 
individual, centrally located tumors from eyes of Kif14;TAg-RB and TAg-RB mice 
over a six week time course was performed. Despite some variability between tumors, 
this analysis revealed a significant decrease in doubling time of individual tumors in 
the double vs. single transgenics, 1.8 weeks vs. 2.9 weeks respectively (p < 0.0001) 
(Figure 2f). 
We also assessed total tumor burden per eye by ex vivo quantification, using 
expression of TAg as an immunohistochemical marker
16
 (which specifically stains 
viable tumor cells in this model) or by histopathology (which also includes necrotic 
tumor cores). The overexpression of Kif14 in TAg-RB resulted in an increased total 
tumor burden (Figure 3), irrespective of quantification method. At week 8 there was 
approximately two-fold more tumor burden per eye in the double vs. single transgenic 
mice (p < 0.05) and this increase was even more marked at week 12 (p < 0.01).  
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Discussion 
We show that the overexpression of Kif14 accelerates tumor onset and increases 
tumor burden and tumor proliferation rate in the TAg-RB retinoblastoma model. This 
provides strong evidence that KIF14 is indeed an oncogene, when considered in 
concert with previous clinical, in vitro and xenograft findings.
10
 
Over-expression of Kif14 in TAg-RB led to an acceleration of tumor formation 
visualized by OCT from as early as week 2. This suggests that Kif14 plays a role in 
enabling tumor initiation, at least in the context of TAg overexpression. The potent 
oncoprotein TAg blocks the function of pRB, p107, p130, and p53, amongst other 
proteins. This readiness of Kif14 to promote growth once pRB is disabled in the 
murine retina echoes what is observed genetically in humans, in the transition from 
benign retinoma (which lacks functional pRB) to proliferating retinoblastoma, which 
also often harbors genomic gain and overexpression of KIF14.  
In TAg-RB, the Kif14-overexpressing tumor cells likely have increased resistance 
to apoptosis; a wave of apoptosis normally kills off the majority of TAg-positive cells 
in TAg-RB eyes around week 4,
17
 while many cells remain when Kif14 is 
overexpressed. Increased apoptosis is a hallmark of Kif14 loss in mice
12
 or 
knockdown in cancer cells in vitro,
10
 so the converse could also be true: Kif14 
overexpression may block apoptosis. 
But increased proliferation appears to be at play as well in Kif14 overexpressing 
cells. Using a novel adaptation of our ellipsoid volumetric quantification method
15
 we 
found that individual tumors in Kif14;TAg-RB mice have significantly faster doubling 
times than those in their TAg-RB littermates. To our knowledge, this is the first 
assessment of doubling times for TAg-RB tumors, made possible by in vivo imaging. 
Interestingly, the observed doubling times in the Kif14;TAg-RB mice are quite 
comparable to those that have been reported for human retinoblastomas (on the order 
of 15 days).
18
 Increased proliferation of Kif14 overexpressing tumor cells is consistent 
with previous in vitro work. Overexpression of KIF14 in hepatocellular carcinoma, 
lung and ovarian cancer cell lines markedly increased their proliferation capacity,
10
 
and a similar effect was seen in immortalized mammary epithelial cells.
11
 It will be 
interesting to assess if Kif14 loss in the context of TAg-RB would slow tumor growth, 
as it does in cell and xenograft models. Since Kif14 knockout is lethal by 21 days of 
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age in mice
12
 and embryonic lethal in humans,
19
 development of conditional 
knockouts of Kif14 to cross into TAg-RB would be required to address this question. 
Alternatively, since Kif14 is a druggable ATPase enzyme,
20
 novel small molecule 
treatments
11
 could be trialed in TAg-RB mice. 
The TAg-RB mouse provides a useful model to test genetic manipulations in 
retinoblastoma. It was previously used to demonstrate the in vivo tumor suppressive 
roles of Cdh11
21
 and p75
NTR
.
22
 But it has not previously been shown that a putative 
oncogene can accelerate tumor growth in the TAg-RB model, as we have done here. 
TAg-RB has a number of advantages over other retinoblastoma mouse models, as it 
bears strong resemblance to the human tumors. It shares the expression pattern of a 
number of genes, including Kif14, with the human disease,
17
 and it is the most 
commonly used model of retinoblastoma for preclinical studies.
23 
The tumors initiate 
in the INL, a possible layer of origin of human tumors, and they contain both Flexner-
Wintersteiner and Homer Wright rosettes, histopathological hallmarks of human 
retinoblastoma that are not seen together in other mouse models of retinoblastoma.
13
 
However, the TAg-RB model has limitations. Induced by specific expression of 
TAg rather than genetic loss of Rb1, it has a different molecular etiology from the 
human disease. Recent work has shown that human retinoblastoma can arise from a 
cone precursor,
24
 while the TAg-RB cell of origin is a Müller glia with progenitor 
properties;
17
 different cell types might respond differently to Kif14 overexpression. 
Moreover, since TAg functionally inactivates p53 and other proteins as well as pRB, 
TAg-RB cells might be particularly susceptible to a putative anti-apoptotic effect of 
Kif14 overexpression, whereas the human cell of origin, which may have functional 
p53, may be less sensitive.  
A further limitation of this study is that we used near-congenic rather than 
completely congenic animals. Thus, we cannot exclude the possibility that a closely 
linked allele to the Kif14 transgene could contribute to the observed phenotypic 
differences. To further support our findings, further backcrosses followed by future 
investigation of Kif14 overexpression in other transgenic retinoblastoma models, and 
in human cell xenograft models of the disease is warranted.
25
 Future high-resolution 
analyses of multiple human and murine retinoblastoma genomes, and correlation with 
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gene expression, will also help to completely define KIF14’s importance in 
retinoblastomagenesis. 
In conclusion, we have demonstrated that overexpression of Kif14 in the TAg-RB 
model of retinoblastoma enhances tumor formation. We report a sustained and 
significant increase in percentage tumor burden in double transgenics compared to 
TAg-RB control mice, providing strong evidence that Kif14 can promote 
retinoblastoma growth in susceptible cells in vivo. We observed increased tumor 
growth rates via OCT analysis and furthermore we present a novel approach to 
document and compare tumor growth in response to genetic manipulations by 
combining OCT and IHC imaging of this model. Our results further substantiate the 
role of Kif14 as an oncogene in the development of retinoblastoma. Given KIF14’s 
importance in other human cancers such as lung, ovarian and breast cancer, it will be 
exciting to use the Kif14 overexpression model in combination with other transgenic 
cancer models to assess the role of Kif14 in murine epithelial cancers and further 
validate Kif14 as a broadly relevant oncogene. 
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Figure Legends 
Figure 1. Kif14 overexpression accelerates tumor initiation in TAg-RB. Increased 
tumor burden in Kif14;TAg-RB mice (b, c, e, f, h, i) vs. TAg-RB controls (a, d, g); the 
retinas of Kif14 single transgenic mice were normal (j). Representative images at 2–4 
weeks of age as visualized by fundus images (upper panels) and OCT (lower panels). 
Example tumor cell clusters are marked (yellow arrowheads); the entire inner nuclear 
layer was filled with early tumor cells in some double transgenic eyes (blue 
arrowheads). The red horizontal line in the fundus images represents the cross 
sectional plane of OCT imaging. Scale bars = 100 µm. 
Figure 2. Increased tumor growth rate in Kif14;TAg-RB mice compared to TAg-RB 
controls. Representative images of tumor burden in Kif14;TAg-RB mice (b, d) 
compared to TAg-RB mice (a, c) at weeks 8 (a, b) and 12 (c, d) of age by funduscopy 
(upper panels) and OCT (lower panels). Example tumor masses are marked with 
yellow arrowheads. Scale bars = 100 µm. (e) Discrete visible tumor number in 
Kif14;TAg-RB eyes vs. TAg-RB control eyes shows a non-significant trend towards a 
difference (p > 0.05; Student’s t-test; n = 4–6 per group). (f) Growth rates of centrally 
located retinoblastomas from Kif14;TAg-RB mice (red lines) (n = 4) and TAg-RB 
control mice (black lines) (n = 3). Doubling times were significantly different (1.8 vs. 
2.9 weeks, p < 0.0001, extra sum of squares F-test). 
Figure 3. Total tumor burden is increased in Kif14;TAg-RB mice compared to TAg-
RB littermate controls. Representative TAg IHC (brown staining) and corresponding 
H&E images of peripheral tumors at 8 (a, c, e, g) and 12 (b, d, f, h) weeks comparing 
TAg-RB mice (a–d) with Kif14;TAg-RB littermates (e–h). Scale bar = 200 µm. 
Quantitative IHC analysis (i) or H&E analysis (j) of percentage tumor burden in 
Kif14;TAg-RB mice compared to TAg-RB controls. Significant differences were 
observed at both weeks 8 and 12 by both methods (*, p < 0.05; **, p < 0.01, Student’s 
t-test, n = 4–6 per group). 
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layer was filled with early tumor cells in some double transgenic eyes (blue arrowheads). The red horizontal 
line in the fundus images represents the cross sectional plane of OCT imaging. Scale bars = 100 µm.  
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Figure 2. Increased tumor growth rate in Kif14;TAg-RB mice compared to TAg-RB controls. Representative 
images of tumor burden in Kif14;TAg-RB mice (b, d) compared to TAg-RB mice (a, c) at weeks 8 (a, b) and 
12 (c, d) of age by funduscopy (upper panels) and OCT (lower panels). Example tumor masses are marked 
with yellow arrowheads. Scale bars = 100 µm. (e) Discrete visible tumor number in Kif14;TAg-RB eyes vs. 
TAg-RB control eyes shows a non-significant trend towards a difference (p > 0.05; Student’s t-test; n = 4–6 
per group). (f) Growth rates of centrally located retinoblastomas from Kif14;TAg-RB mice (red lines) (n = 4) 
and TAg-RB control mice (black lines) (n = 3). Doubling times were significantly different (1.8 vs. 2.9 
weeks, p < 0.0001, extra sum of squares F-test).  
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Figure 3. Total tumor burden is increased in Kif14;TAg-RB mice compared to TAg-RB littermate controls. 
Representative TAg IHC (brown staining) and corresponding H&E images of peripheral tumors at 8 (a, c, e, 
g) and 12 (b, d, f, h) weeks comparing TAg-RB mice (a–d) with Kif14;TAg-RB littermates (e–h). Scale bar = 
200 m. Quantitative IHC analysis (i) or H&E analysis (j) of percentage tumor burden in Kif14;TAg-RB mice 
compared to TAg-RB controls. Significant differences were observed at both weeks 8 and 12 by both 
methods (*, p < 0.05; **, p < 0.01, Student’s t-test, n = 4–6 per group).  
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